Challenges of inhalation drug development

The increasing potential of pulmonary routes of administration for local therapies is driving the development of inhalation drug products. However, developing treatments with this delivery mechanism presents several challenges for manufacturers.

Time to market varies depending on whether a product is a new MDI or DPI, or a product that can be taken down the abbreviated 505(b)(2) route.

Working with a CDMO partner that offers an end-to-end service and has knowledge of inhalation products can help to reduce risk and manage the complexities often experienced during development and manufacturing.  

Shabbir Mostafa, global key account director, at Recipharm discusses the key challenges of inhalation drug development and how working with a CDMO partner can help manage these complexities during both the development and manufacturing stages.

Read the full article here: